127 related articles for article (PubMed ID: 30949858)
21. Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.
Leto SM; Sassi F; Catalano I; Torri V; Migliardi G; Zanella ER; Throsby M; Bertotti A; Trusolino L
Clin Cancer Res; 2015 Dec; 21(24):5519-31. PubMed ID: 26296355
[TBL] [Abstract][Full Text] [Related]
22. A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response.
Xiao Z; Carrasco RA; Schifferli K; Kinneer K; Tammali R; Chen H; Rothstein R; Wetzel L; Yang C; Chowdhury P; Tsui P; Steiner P; Jallal B; Herbst R; Hollingsworth RE; Tice DA
Mol Cancer Ther; 2016 Apr; 15(4):689-701. PubMed ID: 26880266
[TBL] [Abstract][Full Text] [Related]
23. The anti-HER3 antibody in combination with trastuzumab exerts synergistic antitumor activity in HER2-positive gastric cancer.
Wang Q; Zhang X; Shen E; Gao J; Cao F; Wang X; Li Y; Tian T; Wang J; Chen Z; Wang J; Shen L
Cancer Lett; 2016 Sep; 380(1):20-30. PubMed ID: 27317872
[TBL] [Abstract][Full Text] [Related]
24. Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models.
Koussounadis A; Langdon SP; Um I; Kay C; Francis KE; Harrison DJ; Smith VA
BMC Cancer; 2016 Mar; 16():205. PubMed ID: 26964739
[TBL] [Abstract][Full Text] [Related]
25. Dual mTORC1/2 Inhibition as a Novel Strategy for the Resensitization and Treatment of Platinum-Resistant Ovarian Cancer.
Musa F; Alard A; David-West G; Curtin JP; Blank SV; Schneider RJ
Mol Cancer Ther; 2016 Jul; 15(7):1557-67. PubMed ID: 27196780
[TBL] [Abstract][Full Text] [Related]
26. Dasatinib attenuates overexpression of Src signaling induced by the combination treatment of veliparib plus carboplatin in triple-negative breast cancer.
Sun Y; Lin X; Aske JC; Ye P; Williams C; Abramovitz M; Leyland-Jones BR
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1241-1256. PubMed ID: 31541266
[TBL] [Abstract][Full Text] [Related]
27. Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma.
Fattore L; Malpicci D; Marra E; Belleudi F; Noto A; De Vitis C; Pisanu ME; Coluccia P; Camerlingo R; Roscilli G; Ribas A; Di Napoli A; Torrisi MR; Aurisicchio L; Ascierto PA; Mancini R; Ciliberto G
Oncotarget; 2015 Sep; 6(28):24823-41. PubMed ID: 26208478
[TBL] [Abstract][Full Text] [Related]
28. Down-regulation of HECTD3 by HER2 inhibition makes serous ovarian cancer cells sensitive to platinum treatment.
Shu T; Li Y; Wu X; Li B; Liu Z
Cancer Lett; 2017 Dec; 411():65-73. PubMed ID: 28989055
[TBL] [Abstract][Full Text] [Related]
29. Alofanib, an allosteric FGFR2 inhibitor, has potent effects on ovarian cancer growth in preclinical studies.
Tyulyandina A; Harrison D; Yin W; Stepanova E; Kochenkov D; Solomko E; Peretolchina N; Daeyaert F; Joos JB; Van Aken K; Byakhov M; Gavrilova E; Tjulandin S; Tsimafeyeu I
Invest New Drugs; 2017 Apr; 35(2):127-133. PubMed ID: 27812884
[TBL] [Abstract][Full Text] [Related]
30. Modulation of HER3 is a marker of dynamic cell signaling in ovarian cancer: implications for pertuzumab sensitivity.
Nagumo Y; Faratian D; Mullen P; Harrison DJ; Hasmann M; Langdon SP
Mol Cancer Res; 2009 Sep; 7(9):1563-71. PubMed ID: 19737968
[TBL] [Abstract][Full Text] [Related]
31. Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models.
Ponte JF; Ab O; Lanieri L; Lee J; Coccia J; Bartle LM; Themeles M; Zhou Y; Pinkas J; Ruiz-Soto R
Neoplasia; 2016 Dec; 18(12):775-784. PubMed ID: 27889646
[TBL] [Abstract][Full Text] [Related]
32. [The HER3/ERBB3 receptor: the dark side of the ERBB planet].
Larbouret C; Gaborit N; Poul MA; Pèlegrin A; Chardès T
Med Sci (Paris); 2015 May; 31(5):465-8. PubMed ID: 26059291
[No Abstract] [Full Text] [Related]
33. Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft.
Glaser G; Weroha SJ; Becker MA; Hou X; Enderica-Gonzalez S; Harrington SC; Haluska P
PLoS One; 2015; 10(5):e0126867. PubMed ID: 25962155
[TBL] [Abstract][Full Text] [Related]
34. A Novel HER3-Targeting Antibody-Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization.
Hashimoto Y; Koyama K; Kamai Y; Hirotani K; Ogitani Y; Zembutsu A; Abe M; Kaneda Y; Maeda N; Shiose Y; Iguchi T; Ishizaka T; Karibe T; Hayakawa I; Morita K; Nakada T; Nomura T; Wakita K; Kagari T; Abe Y; Murakami M; Ueno S; Agatsuma T
Clin Cancer Res; 2019 Dec; 25(23):7151-7161. PubMed ID: 31471314
[TBL] [Abstract][Full Text] [Related]
35. Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.
Poovassery JS; Kang JC; Kim D; Ober RJ; Ward ES
Int J Cancer; 2015 Jul; 137(2):267-77. PubMed ID: 25471734
[TBL] [Abstract][Full Text] [Related]
36. Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE).
Kurzeder C; Bover I; Marmé F; Rau J; Pautier P; Colombo N; Lorusso D; Ottevanger P; Bjurberg M; Marth C; Barretina-Ginesta P; Vergote I; Floquet A; Del Campo JM; Mahner S; Bastière-Truchot L; Martin N; Oestergaard MZ; Kiermaier A; Schade-Brittinger C; Polleis S; du Bois A; Gonzalez-Martin A
J Clin Oncol; 2016 Jul; 34(21):2516-25. PubMed ID: 27269942
[TBL] [Abstract][Full Text] [Related]
37. A novel anti-HER2 antibody GB235 reverses Trastuzumab resistance in HER2-expressing tumor cells in vitro and in vivo.
Shu M; Yan H; Xu C; Wu Y; Chi Z; Nian W; He Z; Xiao J; Wei H; Zhou Q; Zhou JX
Sci Rep; 2020 Feb; 10(1):2986. PubMed ID: 32076029
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of phosphatidylinositol 3-kinase sensitizes ovarian cancer cells to carboplatin and allows adjunct chemotherapy treatment.
Westfall SD; Skinner MK
Mol Cancer Ther; 2005 Nov; 4(11):1764-71. PubMed ID: 16275998
[TBL] [Abstract][Full Text] [Related]
39. Targeting of mutant p53-induced FoxM1 with thiostrepton induces cytotoxicity and enhances carboplatin sensitivity in cancer cells.
Zhang X; Cheng L; Minn K; Madan R; Godwin AK; Shridhar V; Chien J
Oncotarget; 2014 Nov; 5(22):11365-80. PubMed ID: 25426548
[TBL] [Abstract][Full Text] [Related]
40. BRCA Status Does Not Predict Synergism of a Carboplatin and Olaparib Combination in High-Grade Serous Ovarian Cancer Cell Lines.
Shen YT; Evans JC; Zafarana G; Allen C; Piquette-Miller M
Mol Pharm; 2018 Jul; 15(7):2742-2753. PubMed ID: 29750868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
